Table of Content

1 PD-1 and PDL-1 Inhibitors Market Overview
1.1 Product Overview and Scope of PD-1 and PDL-1 Inhibitors
1.2 PD-1 and PDL-1 Inhibitors Segment by Type
1.2.1 Global PD-1 and PDL-1 Inhibitors Market Value Comparison by Type (2024-2034)
1.2.2 Pembrolizumab
1.2.3 Nivolumab
1.2.4 Atezolizumab
1.2.5 Durvalumab
1.2.6 Avelumab
1.3 PD-1 and PDL-1 Inhibitors Segment by Application
1.3.1 Global PD-1 and PDL-1 Inhibitors Market Value by Application: (2024-2034)
1.3.2 Stomach Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Ccancer
1.3.5 Bladder Cancer
1.3.6 Cervical Cancer
1.3.7 Other
1.4 Global PD-1 and PDL-1 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PDL-1 Inhibitors Revenue 2018-2029
1.4.2 Global PD-1 and PDL-1 Inhibitors Sales 2018-2029
1.4.3 Global PD-1 and PDL-1 Inhibitors Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PD-1 and PDL-1 Inhibitors Market Competition by Manufacturers
2.1 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Manufacturers (2018-2024)
2.2 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Manufacturers (2018-2024)
2.3 Global PD-1 and PDL-1 Inhibitors Average Price by Manufacturers (2018-2024)
2.4 Global PD-1 and PDL-1 Inhibitors Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Product Type & Application
2.7 PD-1 and PDL-1 Inhibitors Market Competitive Situation and Trends
2.7.1 PD-1 and PDL-1 Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1 and PDL-1 Inhibitors Players Market Share by Revenue
2.7.3 Global PD-1 and PDL-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1 and PDL-1 Inhibitors Retrospective Market Scenario by Region
3.1 Global PD-1 and PDL-1 Inhibitors Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global PD-1 and PDL-1 Inhibitors Global PD-1 and PDL-1 Inhibitors Sales by Region: 2018-2029
3.2.1 Global PD-1 and PDL-1 Inhibitors Sales by Region: 2018-2024
3.2.2 Global PD-1 and PDL-1 Inhibitors Sales by Region: 2024-2029
3.3 Global PD-1 and PDL-1 Inhibitors Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2018-2029
3.3.1 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2018-2024
3.3.2 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2024-2029
3.4 North America PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.4.1 North America PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.4.3 North America PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.5.3 Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1 and PDL-1 Inhibitors Sales by Type (2018-2029)
4.1.1 Global PD-1 and PDL-1 Inhibitors Sales by Type (2018-2024)
4.1.2 Global PD-1 and PDL-1 Inhibitors Sales by Type (2024-2029)
4.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2018-2029)
4.2 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2018-2029)
4.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2018-2024)
4.2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2024-2029)
4.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Type (2018-2029)
4.3 Global PD-1 and PDL-1 Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global PD-1 and PDL-1 Inhibitors Sales by Application (2018-2029)
5.1.1 Global PD-1 and PDL-1 Inhibitors Sales by Application (2018-2024)
5.1.2 Global PD-1 and PDL-1 Inhibitors Sales by Application (2024-2029)
5.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2018-2029)
5.2 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2018-2029)
5.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2018-2024)
5.2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2024-2029)
5.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2018-2029)
5.3 Global PD-1 and PDL-1 Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 GlaxoSmithKline plc
6.1.1 GlaxoSmithKline plc Corporation Information
6.1.2 GlaxoSmithKline plc Description and Business Overview
6.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolio
6.1.5 GlaxoSmithKline plc Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Corporation Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Arcus Biosciences, Inc.
6.3.1 Arcus Biosciences, Inc. Corporation Information
6.3.2 Arcus Biosciences, Inc. Description and Business Overview
6.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolio
6.3.5 Arcus Biosciences, Inc. Recent Developments/Updates
6.4 Agenus Inc
6.4.1 Agenus Inc Corporation Information
6.4.2 Agenus Inc Description and Business Overview
6.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolio
6.4.5 Agenus Inc Recent Developments/Updates
6.5 F. Hoffmann-La Roche Ltd
6.5.1 F. Hoffmann-La Roche Ltd Corporation Information
6.5.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.5.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.6 Astra Zeneca PLC
6.6.1 Astra Zeneca PLC Corporation Information
6.6.2 Astra Zeneca PLC Description and Business Overview
6.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolio
6.6.5 Astra Zeneca PLC Recent Developments/Updates
6.7 Beigene Ltd
6.6.1 Beigene Ltd Corporation Information
6.6.2 Beigene Ltd Description and Business Overview
6.6.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.7.5 Beigene Ltd Recent Developments/Updates
6.8 Incyte Corporation
6.8.1 Incyte Corporation Corporation Information
6.8.2 Incyte Corporation Description and Business Overview
6.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolio
6.8.5 Incyte Corporation Recent Developments/Updates
6.9 Biocad
6.9.1 Biocad Corporation Information
6.9.2 Biocad Description and Business Overview
6.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Biocad PD-1 and PDL-1 Inhibitors Product Portfolio
6.9.5 Biocad Recent Developments/Updates
6.10 CStone Pharmaceuticals
6.10.1 CStone Pharmaceuticals Corporation Information
6.10.2 CStone Pharmaceuticals Description and Business Overview
6.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolio
6.10.5 CStone Pharmaceuticals Recent Developments/Updates
6.11 Ono Pharmaceutical
6.11.1 Ono Pharmaceutical Corporation Information
6.11.2 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Description and Business Overview
6.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolio
6.11.5 Ono Pharmaceutical Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck PD-1 and PDL-1 Inhibitors Description and Business Overview
6.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Merck PD-1 and PDL-1 Inhibitors Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Shanghai Junshi Bioscience Co. Ltd
6.13.1 Shanghai Junshi Bioscience Co. Ltd Corporation Information
6.13.2 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Description and Business Overview
6.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.13.5 Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
6.14 Shanghai Henlius Biotech, Inc.
6.14.1 Shanghai Henlius Biotech, Inc. Corporation Information
6.14.2 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Description and Business Overview
6.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolio
6.14.5 Shanghai Henlius Biotech, Inc. Recent Developments/Updates
6.15 Jiangsu HengRui Medicine Co., Ltd.
6.15.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.15.2 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Description and Business Overview
6.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolio
6.15.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1 and PDL-1 Inhibitors Industry Chain Analysis
7.2 PD-1 and PDL-1 Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1 and PDL-1 Inhibitors Production Mode & Process
7.4 PD-1 and PDL-1 Inhibitors Sales and Marketing
7.4.1 PD-1 and PDL-1 Inhibitors Sales Channels
7.4.2 PD-1 and PDL-1 Inhibitors Distributors
7.5 PD-1 and PDL-1 Inhibitors Customers
8 PD-1 and PDL-1 Inhibitors Market Dynamics
8.1 PD-1 and PDL-1 Inhibitors Industry Trends
8.2 PD-1 and PDL-1 Inhibitors Market Drivers
8.3 PD-1 and PDL-1 Inhibitors Market Challenges
8.4 PD-1 and PDL-1 Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global PD-1 and PDL-1 Inhibitors Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global PD-1 and PDL-1 Inhibitors Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global PD-1 and PDL-1 Inhibitors Market Competitive Situation by Manufacturers in 2022
Table 4. Global PD-1 and PDL-1 Inhibitors Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Manufacturers (2018-2024)
Table 6. Global PD-1 and PDL-1 Inhibitors Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global PD-1 and PDL-1 Inhibitors Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market PD-1 and PDL-1 Inhibitors Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of PD-1 and PDL-1 Inhibitors, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PD-1 and PDL-1 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PDL-1 Inhibitors as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PD-1 and PDL-1 Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global PD-1 and PDL-1 Inhibitors Sales by Region (2018-2024) & (K Units)
Table 18. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Region (2018-2024)
Table 19. Global PD-1 and PDL-1 Inhibitors Sales by Region (2024-2029) & (K Units)
Table 20. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Region (2024-2029)
Table 21. Global PD-1 and PDL-1 Inhibitors Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Region (2018-2024)
Table 23. Global PD-1 and PDL-1 Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Region (2024-2029)
Table 25. North America PD-1 and PDL-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America PD-1 and PDL-1 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 27. North America PD-1 and PDL-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 28. North America PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America PD-1 and PDL-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe PD-1 and PDL-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe PD-1 and PDL-1 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 32. Europe PD-1 and PDL-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 33. Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America PD-1 and PDL-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America PD-1 and PDL-1 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 42. Latin America PD-1 and PDL-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 43. Latin America PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America PD-1 and PDL-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global PD-1 and PDL-1 Inhibitors Sales (K Units) by Type (2018-2024)
Table 51. Global PD-1 and PDL-1 Inhibitors Sales (K Units) by Type (2024-2029)
Table 52. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2018-2024)
Table 53. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2024-2029)
Table 54. Global PD-1 and PDL-1 Inhibitors Revenue (US$ Million) by Type (2018-2024)
Table 55. Global PD-1 and PDL-1 Inhibitors Revenue (US$ Million) by Type (2024-2029)
Table 56. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Type (2018-2024)
Table 57. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Type (2024-2029)
Table 58. Global PD-1 and PDL-1 Inhibitors Price (US$/Unit) by Type (2018-2024)
Table 59. Global PD-1 and PDL-1 Inhibitors Price (US$/Unit) by Type (2024-2029)
Table 60. Global PD-1 and PDL-1 Inhibitors Sales (K Units) by Application (2018-2024)
Table 61. Global PD-1 and PDL-1 Inhibitors Sales (K Units) by Application (2024-2029)
Table 62. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2018-2024)
Table 63. Global PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2024-2029)
Table 64. Global PD-1 and PDL-1 Inhibitors Revenue (US$ Million) by Application (2018-2024)
Table 65. Global PD-1 and PDL-1 Inhibitors Revenue (US$ Million) by Application (2024-2029)
Table 66. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2018-2024)
Table 67. Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2024-2029)
Table 68. Global PD-1 and PDL-1 Inhibitors Price (US$/Unit) by Application (2018-2024)
Table 69. Global PD-1 and PDL-1 Inhibitors Price (US$/Unit) by Application (2024-2029)
Table 70. GlaxoSmithKline plc Corporation Information
Table 71. GlaxoSmithKline plc Description and Business Overview
Table 72. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product
Table 74. GlaxoSmithKline plc Recent Developments/Updates
Table 75. Bristol-Myers Squibb Company Corporation Information
Table 76. Bristol-Myers Squibb Company Description and Business Overview
Table 77. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product
Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
Table 80. Arcus Biosciences, Inc. Corporation Information
Table 81. Arcus Biosciences, Inc. Description and Business Overview
Table 82. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product
Table 84. Arcus Biosciences, Inc. Recent Developments/Updates
Table 85. Agenus Inc Corporation Information
Table 86. Agenus Inc Description and Business Overview
Table 87. Agenus Inc PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Agenus Inc PD-1 and PDL-1 Inhibitors Product
Table 89. Agenus Inc Recent Developments/Updates
Table 90. F. Hoffmann-La Roche Ltd Corporation Information
Table 91. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 92. F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product
Table 94. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 95. Astra Zeneca PLC Corporation Information
Table 96. Astra Zeneca PLC Description and Business Overview
Table 97. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product
Table 99. Astra Zeneca PLC Recent Developments/Updates
Table 100. Beigene Ltd Corporation Information
Table 101. Beigene Ltd Description and Business Overview
Table 102. Beigene Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Beigene Ltd PD-1 and PDL-1 Inhibitors Product
Table 104. Beigene Ltd Recent Developments/Updates
Table 105. Incyte Corporation Corporation Information
Table 106. Incyte Corporation Description and Business Overview
Table 107. Incyte Corporation PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Incyte Corporation PD-1 and PDL-1 Inhibitors Product
Table 109. Incyte Corporation Recent Developments/Updates
Table 110. Biocad Corporation Information
Table 111. Biocad Description and Business Overview
Table 112. Biocad PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Biocad PD-1 and PDL-1 Inhibitors Product
Table 114. Biocad Recent Developments/Updates
Table 115. CStone Pharmaceuticals Corporation Information
Table 116. CStone Pharmaceuticals Description and Business Overview
Table 117. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product
Table 119. CStone Pharmaceuticals Recent Developments/Updates
Table 120. Ono Pharmaceutical Corporation Information
Table 121. Ono Pharmaceutical Description and Business Overview
Table 122. Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product
Table 124. Ono Pharmaceutical Recent Developments/Updates
Table 125. Merck Corporation Information
Table 126. Merck Description and Business Overview
Table 127. Merck PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Merck PD-1 and PDL-1 Inhibitors Product
Table 129. Merck Recent Developments/Updates
Table 130. Shanghai Junshi Bioscience Co. Ltd Corporation Information
Table 131. Shanghai Junshi Bioscience Co. Ltd Description and Business Overview
Table 132. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product
Table 134. Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
Table 135. Shanghai Henlius Biotech, Inc. Corporation Information
Table 136. Shanghai Henlius Biotech, Inc. Description and Business Overview
Table 137. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product
Table 139. Shanghai Henlius Biotech, Inc. Recent Developments/Updates
Table 140. Jiangsu HengRui Medicine Co., Ltd. Corporation Information
Table 141. Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
Table 142. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product
Table 144. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. PD-1 and PDL-1 Inhibitors Distributors List
Table 148. PD-1 and PDL-1 Inhibitors Customers List
Table 149. PD-1 and PDL-1 Inhibitors Market Trends
Table 150. PD-1 and PDL-1 Inhibitors Market Drivers
Table 151. PD-1 and PDL-1 Inhibitors Market Challenges
Table 152. PD-1 and PDL-1 Inhibitors Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of PD-1 and PDL-1 Inhibitors
Figure 2. Global PD-1 and PDL-1 Inhibitors Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global PD-1 and PDL-1 Inhibitors Market Share by Type in 2022 & 2029
Figure 4. Pembrolizumab Product Picture
Figure 5. Nivolumab Product Picture
Figure 6. Atezolizumab Product Picture
Figure 7. Durvalumab Product Picture
Figure 8. Avelumab Product Picture
Figure 9. Global PD-1 and PDL-1 Inhibitors Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 10. Global PD-1 and PDL-1 Inhibitors Market Share by Application in 2022 & 2029
Figure 11. Stomach Cancer
Figure 12. Liver Cancer
Figure 13. Kidney Ccancer
Figure 14. Bladder Cancer
Figure 15. Cervical Cancer
Figure 16. Other
Figure 17. Global PD-1 and PDL-1 Inhibitors Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global PD-1 and PDL-1 Inhibitors Market Size (2018-2029) & (US$ Million)
Figure 19. Global PD-1 and PDL-1 Inhibitors Sales (2018-2029) & (K Units)
Figure 20. Global PD-1 and PDL-1 Inhibitors Average Price (US$/Unit) & (2018-2029)
Figure 21. PD-1 and PDL-1 Inhibitors Report Years Considered
Figure 22. PD-1 and PDL-1 Inhibitors Sales Share by Manufacturers in 2022
Figure 23. Global PD-1 and PDL-1 Inhibitors Revenue Share by Manufacturers in 2022
Figure 24. The Global 5 and 10 Largest PD-1 and PDL-1 Inhibitors Players: Market Share by Revenue in 2022
Figure 25. PD-1 and PDL-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 26. Global PD-1 and PDL-1 Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 27. North America PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 28. North America PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 29. United States PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Canada PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Europe PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 32. Europe PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 33. Germany PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. France PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. U.K. PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Italy PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Russia PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Asia Pacific PD-1 and PDL-1 Inhibitors Sales Market Share by Region (2018-2029)
Figure 39. Asia Pacific PD-1 and PDL-1 Inhibitors Revenue Market Share by Region (2018-2029)
Figure 40. China PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Japan PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. South Korea PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. India PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Australia PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. China Taiwan PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Indonesia PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Thailand PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Malaysia PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 50. Latin America PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 51. Mexico PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 55. Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 56. Turkey PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. UAE PD-1 and PDL-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Global Sales Market Share of PD-1 and PDL-1 Inhibitors by Type (2018-2029)
Figure 60. Global Revenue Market Share of PD-1 and PDL-1 Inhibitors by Type (2018-2029)
Figure 61. Global PD-1 and PDL-1 Inhibitors Price (US$/Unit) by Type (2018-2029)
Figure 62. Global Sales Market Share of PD-1 and PDL-1 Inhibitors by Application (2018-2029)
Figure 63. Global Revenue Market Share of PD-1 and PDL-1 Inhibitors by Application (2018-2029)
Figure 64. Global PD-1 and PDL-1 Inhibitors Price (US$/Unit) by Application (2018-2029)
Figure 65. PD-1 and PDL-1 Inhibitors Value Chain
Figure 66. PD-1 and PDL-1 Inhibitors Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed